These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31404304)

  • 21. Novel BCR-ABL1 fusion and leukemic mutations of SETBP1, PAX5, and TP53 detected by next generation sequencing in chronic myeloid leukemia.
    Fu S; Hu Y; Fu Y; Chen F; Liu X; Zhang M; Wang X; Tu S; Zhang J
    Cancer Biol Ther; 2016 Oct; 17(10):1003-1009. PubMed ID: 27611742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic Myeloid Leukemia with b3a3 (e14a3) Fusion: A Rare BCR/ABL Rearrangement Presenting with Thrombocytosis - Does MTHFR Polymorphism Matter.
    Chisti MM; Sanders DS
    Case Rep Oncol; 2018; 11(2):485-492. PubMed ID: 30140211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical
    Massimino M; Tirrò E; Stella S; Manzella L; Pennisi MS; Romano C; Vitale SR; Puma A; Tomarchio C; Di Gregorio S; Antolino A; Di Raimondo F; Vigneri P
    Front Pharmacol; 2021; 12():669469. PubMed ID: 34276365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the
    Stella S; Gottardi EM; Favout V; Barragan Gonzalez E; Errichiello S; Vitale SR; Fava C; Luciano L; Stagno F; Grimaldi F; Pironi L; Sargas Simarro C; Vigneri P; Izzo B
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel Multiplex Droplet Digital PCR Assays to Monitor Minimal Residual Disease in Chronic Myeloid Leukemia Patients Showing Atypical
    Petiti J; Lo Iacono M; Dragani M; Pironi L; Fantino C; Rapanotti MC; Quarantelli F; Izzo B; Divona M; Rege-Cambrin G; Saglio G; Gottardi EM; Cilloni D; Fava C
    J Clin Med; 2020 May; 9(5):. PubMed ID: 32414125
    [No Abstract]   [Full Text] [Related]  

  • 26. Characterization of a novel variant BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring.
    Crampe M; Haslam K; Kelly J; Conneally E; Langabeer SE
    Hematol Oncol Stem Cell Ther; 2017 Jun; 10(2):85-88. PubMed ID: 27013275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR.
    Zagaria A; Anelli L; Coccaro N; Tota G; Casieri P; Cellamare A; Impera L; Brunetti C; Minervini A; Minervini CF; Delia M; Cumbo C; Orsini P; Specchia G; Albano F
    Virchows Arch; 2015 Sep; 467(3):357-63. PubMed ID: 26149409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
    Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
    BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to Imatinib.
    Popovici C; Cailleres S; David M; Lafage-Pochitaloff M; Sainty D; Mozziconacci MJ
    Leuk Lymphoma; 2005 Sep; 46(9):1375-7. PubMed ID: 16109618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new aberrantly spliced
    Naumann N; Bross-Bach U; Seifarth W; Fabarius A; Hofmann WK; Saußele S; Spiess B
    EJHaem; 2022 Nov; 3(4):1339-1342. PubMed ID: 36467807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.
    Foroni L; Gerrard G; Nna E; Khorashad JS; Stevens D; Swale B; Milojkovic D; Reid A; Goldman J; Marin D
    Am J Hematol; 2009 Aug; 84(8):517-22. PubMed ID: 19544476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic myeloid leukemia with e14a3 BCR-ABL transcript: analysis of characteristics and prognostic significance.
    Gui X; Zhang Y; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y
    Leuk Lymphoma; 2015; 56(12):3343-7. PubMed ID: 25962435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High reliability and sensitivity of the BCR/ABL1 D-FISH test for the detection of BCR/ABL rearrangements.
    Pelz AF; Kröning H; Franke A; Wieacker P; Stumm M
    Ann Hematol; 2002 Mar; 81(3):147-53. PubMed ID: 11904740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytogenetic, fluorescence in situ hybridization, and genomic array characterization of chronic myeloid leukemia with cryptic BCR-ABL1 fusions.
    Shao L; Miller S; Keller-Ramey J; Zhang Y; Roulston D
    Cancer Genet; 2015; 208(7-8):396-403. PubMed ID: 26186983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib.
    Pagnano KBB; Miranda EC; Delamain MT; Duarte GO; de Paula EV; Lorand-Metze I; de Souza CA
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):728-733. PubMed ID: 28822797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia.
    Moore FR; Rempfer CB; Press RD
    Methods Mol Biol; 2013; 999():1-23. PubMed ID: 23666687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia.
    Loncarevic IF; Römer J; Starke H; Heller A; Bleck C; Ziegler M; Fiedler W; Liehr T; Clement JH; Claussen U
    Genes Chromosomes Cancer; 2002 Jun; 34(2):193-200. PubMed ID: 11979553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
    Castagnetti F; Gugliotta G; Breccia M; Iurlo A; Levato L; Albano F; Vigneri P; Abruzzese E; Rossi G; Rupoli S; Cavazzini F; Martino B; Orlandi E; Pregno P; Annunziata M; Usala E; Tiribelli M; Sica S; Bonifacio M; Fava C; Gherlinzoni F; Bocchia M; Soverini S; Bochicchio MT; Cavo M; Giovanni M; Saglio G; Pane F; Baccarani M; Rosti G;
    Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BCR-ABL1 transcript levels increase in peripheral blood but not in granulocytes after physical exercise in patients with chronic myeloid leukemia.
    Jönsson S; Olsson B; Jacobsson S; Palmqvist L; Ricksten A; Ekeland-Sjöberg K; Wadenvik H
    Scand J Clin Lab Invest; 2011 Feb; 71(1):7-11. PubMed ID: 20863169
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Pagani IS; Dang P; Kommers IO; Goyne JM; Nicola M; Saunders VA; Braley J; White DL; Yeung DT; Branford S; Hughes TP; Ross DM
    Haematologica; 2018 Dec; 103(12):2026-2032. PubMed ID: 29976745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.